WCCS 2022 | Role of neoadjuvant and precision therapeutics in advanced basal cell carcinoma

Susana Puig Sardá, MD, PhD, Hospital Clínic Barcelona, Barcelona, Spain, discusses the role of neoadjuvant in advanced basal cell carcinoma (BCC) and precision therapeutic in BCC. BCC can be treated and cured with appropriate surgery in the majority of cases and in superficial disease noninvasive treatment can sometimes be applied. However, a small proportion of cases can progress or appear in areas that render surgical removal unfeasible or esthetically compromising. In such cases, systemic therapies can reduce the size of the tumor, enabling for surgical removal. This interview took place at the 18th World Congress on Cancers of the Skin (WCCS 2022) in Buenos Aires, Argentina.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.